Skip to main content
SpringerLink
Log in

Dermal and Subcutaneous Chronic Graft-Versus-Host Disease

  • Chapter
  • First Online:
Atlas of Graft-versus-Host Disease

  • 1076 Accesses

Abstract

Dermal and subcutaneous chronic graft-versus-host disease (cGVHD) is a severely restricting form of cGVHD, which may begin insidiously before progressing to ulcerations, limb movement limitations, and even restrictive lung disease. Multiple studies have demonstrated the use of total body irradiation and mobilized stem cells as risks for this form of cGVHD. As more peripheral blood-based hematopoietic stem cell transplants (HSCT) are performed, the incidence of this form of cGVHD is likely to increase. Several unique clinical signs can help to identify early disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755–61.

    Article  CAS  PubMed  Google Scholar 

  2. Atkinson BK, Horowitz MM, Gale RP, Bekkum DW, Van GE, RA G, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459–64.

    CAS  PubMed  Google Scholar 

  3. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 2012;66:515.e1–18.

    Google Scholar 

  4. Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood. 2013;121:5098–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011;118:4250–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Martires KJ, Baird K, Citrin DE, Hakim FT, Pavletic SZ, Cowen EW. Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury. Arch Dermatol. 2011;147:1081–6.

    Article  PubMed  Google Scholar 

  7. Mehra T, Metzler G, Bauer J, Köberle M, Garbe C. Isotopic response of graft versus host disease following herpes zoster infection: case report and review of the literature. Acta Derm Venereol. 2012;92:383–4.

    Article  PubMed  Google Scholar 

  8. Spalek M, Jonska-Gmyrek J, Gałecki J. Radiation-induced morphea – a literature review. J Eur Acad Dermatol Venereol. 2015;29:197–202.

    Article  CAS  PubMed  Google Scholar 

  9. Kaffenberger BH, Zuo RC, Gru A, Plotner AN, Sweeney SA, Devine SM, et al. Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity. J Am Acad Dermatol. 2014;71:745–53.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jacobsohn D, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the chronic GVHD consortium. Blood. 2012;120:2545–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lee SJ. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–14.

    Article  CAS  PubMed  Google Scholar 

  12. Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011;96:1678–84.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lee SK, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:444–52.

    Article  PubMed  Google Scholar 

  14. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium. Blood. 2011;117:4651–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.

    Article  PubMed  Google Scholar 

  16. Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 2014;99:1618–23.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol. 2001;137:1202–6.

    Article  CAS  PubMed  Google Scholar 

  18. Breuckmann F, Gambichler T, Altmeyer P, Kreuter AUVA. UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. 2004;4:11.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22:1179–83.

    Article  CAS  PubMed  Google Scholar 

  20. Sorenson E, McAndrew R, Patel V, Logan AC, Koo J, Levin E. Narrowband UV-B phototherapy for steroid-refractory sclerotic chronic cutaneous graft-vs-host disease. JAMA Dermatol. 2015;151:635.

    Article  PubMed  Google Scholar 

  21. Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: Expanding the sclerodermoid spectrum. J Am Acad Dermatol. 2005;53:591–601.

    Article  PubMed  Google Scholar 

  22. Gottlöber P, Leiter U, Friedrich W, Bunjes D, Schulz A, Kerscher M, Peter RU. Chronic cutaneous sclerodermoid graft-versus-host disease: evaluation by 20-MHz sonography. J Eur Acad Dermatol Venereol. 2003;17:402–7.

    Article  PubMed  Google Scholar 

  23. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlöber P, Peter R, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol. 2000;42:134–6.

    Article  CAS  PubMed  Google Scholar 

  24. Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica. 2003;88:1169–75.

    Google Scholar 

  25. Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant. 2005;35:515–9.

    Article  CAS  PubMed  Google Scholar 

  26. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51.

    Article  CAS  PubMed  Google Scholar 

  27. Martin P, Storer B, Rowley S, Flowers M, Lee S, Carpenter P, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113:5074–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409–17.

    Article  CAS  PubMed  Google Scholar 

  29. Jurado M, Vallejo C, Pérez-Simón J, Brunet S, Ferra C, Balsalobre P, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:701–6.

    Article  CAS  PubMed  Google Scholar 

  30. Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdtfeger R, Schleuning M. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant. 2011;17:657–63.

    Article  CAS  PubMed  Google Scholar 

  31. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:47–55.

    Article  CAS  PubMed  Google Scholar 

  32. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 2003;102:1217–23.

    Article  CAS  PubMed  Google Scholar 

  33. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074–80.

    Article  CAS  PubMed  Google Scholar 

  34. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667–74.

    Article  CAS  PubMed  Google Scholar 

  35. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505–11.

    Article  CAS  PubMed  Google Scholar 

  36. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2016;22:319–27.

    Article  CAS  PubMed  Google Scholar 

  37. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15:1005–13.

    Article  CAS  PubMed  Google Scholar 

  38. Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:1083–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood. 2012;120:5089–90.

    Article  PubMed  Google Scholar 

  40. Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra43.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055–2066.

    Google Scholar 

  44. Svensson LG, Ph D, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–66.

    Article  Google Scholar 

  45. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124:4867–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft- versus-host disease in mice. PLoS One. 2015;10:e0137641.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report. Biol Blood Marrow Transplant. 2006;12:31–47.

    Article  PubMed  Google Scholar 

  48. Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease. Arch Dermatol. 2002;138:924–34.

    Article  PubMed  Google Scholar 

  49. Bruggen MC, Klein I, Greinix H, Bauer W, Kuzmina Z, Rabitsch W, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood. 2014;123:290–9.

    Article  PubMed  Google Scholar 

  50. Willemze AJ, Bakker AC, von dem Borne PA, Bajema IM, Vossen JM. The effect of graft-versus-host disease on skin endothelial and epithelial cell chimerism in stem-cell transplant recipients. Transplantation. 2009;87:1096–101.

    Article  PubMed  Google Scholar 

  51. Ogawa Y, Kodama H, Kameyama K, Yamazaki K, Yasuoka H, Okamoto S, et al. Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. Investig Ophthalmol Vis Sci. 2005;46:4519–27.

    Article  Google Scholar 

  52. Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, et al. Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease and GVHD-associated angiomatosis. Br J Dermatol 2016. doi:10.1111/bjd.14484 [Epub ahead of print].

  53. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–6.

    Article  PubMed  Google Scholar 

  54. Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev. 2001;23:231–47.

    Article  CAS  PubMed  Google Scholar 

  55. Lucas DR. Angiosarcoma, radiation-associated angiosarcoma, and atypical vascular lesion. Arch Pathol Lab Med. 2009;133:1804–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, The Ohio State University Wexner Medical Center, 2012 Kenny Road, 2nd Floor, Columbus, OH, 43214, USA

    Benjamin H. Kaffenberger

  2. Department of Internal Medicine, Division of Hematology, The Ohio State University Wexner Medical Center, 400 West 10th Avenue, Columbus, OH, 43220, USA

    Samantha M. Jaglowski

Authors
  1. Benjamin H. Kaffenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samantha M. Jaglowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin H. Kaffenberger .

Editor information

Editors and Affiliations

  1. Division of Dermatology, City of Hope National Medical Center Division of Dermatology, Durante, California, USA

    Jonathan A. Cotliar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kaffenberger, B.H., Jaglowski, S.M. (2017). Dermal and Subcutaneous Chronic Graft-Versus-Host Disease. In: Cotliar, J. (eds) Atlas of Graft-versus-Host Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-46952-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46952-2_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46950-8

  • Online ISBN: 978-3-319-46952-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation